Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
暂无分享,去创建一个
M. Sormani | E. Radue | M. Freedman | P. Sørensen | M. Blinkenberg | L. Brundin | M. Battaglia | J. Marriott | I. Schiavetti | A. Uccelli | J. Wuerfel | A. Laroni | M. Clanet | P. Muraro | Rehiana Ali | S. Nabavi | R. Oliveri | J. Sellner | C. Tello | Ó. Fernández | James J Marriott
[1] F. Paul,et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. , 2020, Brain : a journal of neurology.
[2] G. Forloni,et al. Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer’s mice , 2020, Cell Death & Differentiation.
[3] L. Brundin,et al. Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis—A Phase I Study , 2019, Journal of clinical medicine.
[4] Jeffrey A. Cohen,et al. Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation , 2019, Multiple sclerosis journal - experimental, translational and clinical.
[5] C. Garlanda,et al. Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure , 2019, Acta Neuropathologica.
[6] M. Sormani,et al. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis , 2019, Trials.
[7] J. Galipeau,et al. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. , 2018, Cell stem cell.
[8] Jeffrey A. Cohen,et al. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis , 2018, Multiple sclerosis.
[9] A. Diaspro,et al. IFN‐&ggr; orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways , 2017, The Journal of allergy and clinical immunology.
[10] J. M. Centanni,et al. Biodistribution and Clearance of Human Mesenchymal Stem Cells by Quantitative Three-Dimensional Cryo-Imaging After Intravenous Infusion in a Rat Lung Injury Model , 2016, Stem cells translational medicine.
[11] E. Andreu,et al. Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis , 2014, PloS one.
[12] Jeffrey A. Cohen,et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.
[13] Arnold I Caplan,et al. Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models , 2012, Nature Neuroscience.
[14] David H. Miller,et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study , 2012, The Lancet Neurology.
[15] F. Barkhof,et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial , 2011, The Lancet.
[16] M. Freedman,et al. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases , 2011, The Lancet Neurology.
[17] Jeff W M Bulte,et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. , 2010, Archives of neurology.
[18] R. Mahfouz,et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study , 2010, Journal of Neuroimmunology.
[19] Ludwig Kappos,et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[20] H. Atkins,et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group , 2010, Multiple sclerosis.
[21] L. Vergani,et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo , 2009, Journal of neurochemistry.
[22] P. Delafontaine,et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. , 2009, Cell stem cell.
[23] N. Shanks,et al. Are animal models predictive for humans? , 2009, Philosophy, ethics, and humanities in medicine : PEHM.
[24] A. Uccelli,et al. Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.
[25] G. Dini,et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.
[26] Antonio Uccelli,et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis , 2007, Annals of neurology.
[27] Ly Sun,et al. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus , 2007, Lupus.
[28] M. Chopp,et al. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice , 2006, Journal of neuroscience research.
[29] L. Lejeune,et al. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. , 2005, Blood.
[30] G. Mancardi,et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.
[31] S. Mckercher,et al. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. , 2000, Science.
[32] F. Barkhof,et al. Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results , 1999, Journal of neurology, neurosurgery, and psychiatry.
[33] J. Taubenberger,et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.
[34] A. Friedenstein,et al. HETEROTOPIC TRANSPLANTS OF BONE MARROW , 1968 .